Publications by authors named "Julia F Markusen"
Article Synopsis
- Representative materials needed for early development of therapeutic proteins can be generated more efficiently using stable transfection pool technology, which can produce gram quantities of monoclonal antibodies (Mabs) quickly.
- This method can achieve expression levels of Mabs ranging from 100 mg/L to over 1000 mg/L and has been successfully scaled up to a 200 L bioreactor for rapid implementation.
- Additionally, using fluorescence-activated cell sorting to enhance high-producer pools can increase productivity three-fold, and optimal production timing is crucial for maintaining yield, with the incorporation of Universal chromatin-opening elements improving overall productivity.
Chinese hamster ovary cells (CHO) have been extensively utilized as the production platform for therapeutic proteins including monoclonal antibodies in pharmaceutical industry. For early development, it would be advantageous to rapidly produce large amounts of protein in the same cell line; therefore, development of a CHO transient transfection platform with high protein expression level is highly desirable. Here, we describe the development of such a platform in CHO cells.
View Article and Find Full Text PDFThis study demonstrates that adult human mesenchymal cells (MSC) can be encapsulated in alginate beads with a substantially retained viability (>80%) and that a Gly-Arg-Gly-Asp-Tyr (GRGDY) derivative encourages attachment and elongation to form a dense network of cells that is required for a tissue substitute. Because the availability of autologous human material is severely limited, we used and examined the beads in this study as a proxy for larger constructs. These bead constructs were assessed using phase contrast microscopy and standard histological preparations.
View Article and Find Full Text PDF